ClinicalTrials.gg
RecruitingNCT06398158AMAZEUpdated Oct 13, 2026

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

An observational study in Neuromyelitis Optica, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Texas Southwestern Medical Center · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Neuromyelitis Optica with a site in United States — 16 open to participants now, 21 under way, 2 of them phase 3. Neuromyelitis Optica · United States.

Planned enrollment
13th of 15
35 · median 112
Started
2024
with 3 others
Observational
15 of 52
8 open now
Primary completion
2029-04
later than 12 of 20 live
Registered
49th of 52
by date
Lead sponsor
3 of 52
University of Texas Southwestern Medical Center

Among the 52 studies in Neuromyelitis Optica with a site in United States, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 49th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

16 of the 52 studies in Neuromyelitis Optica with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Neuromyelitis Optica with a site in United States, or all of them as a file.
02

Study summary

This is an observational study to:

  • evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure),
  • enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab,
  • identify factors suggestive of subclinical disease progression through conventional MRI sequences,
  • determine if treatment with ravulizumab, impacts longitudinal 3D conformational MRI measures at the dorsal medulla and other regions of the CNS, and
  • identify biomarkers (e.g., serum neurofilament light chain (sNfL), conventional and novel MRI markers, etc.) related to disease activity.
Read the detailed description

This is a single-center prospective observational study with all participants recruited from The University of Texas Southwestern Medical Center in Dallas, Texas. Enrollment of 35 people with aquaporin-4 IgG antibody positive neuromyelitis optica spectrum disorder is planned with all individuals treated with commercially supplied ravulizumab at the recommendation of the healthcare provider, with use consistent with the approved indication and labeling.

The study is composed of the following:

  1. Study screening: Study screening will occur up to 45 days, with a minimum of 3 days to allow for the scheduling of study related events. During this time the eligibility of participants will be evaluated and diagnosis of aquaporin 4-IgG positive neuromyelitis optica spectrum confirmed by both the Core Clinical Committee and Core Imaging Committee. If a subject is declared a screen failure, all reasons for ineligibility will be captured. Ineligible subjects may be rescreened at a later time.
  2. Open-label treatment with commercially covered ravulizumab: Enrolled subjects will be treated with ravulizumab in a manner consistent with the FDA approved labeling. All prescreening laboratory tests, vaccinations, and clinical surveillance studies will be ordered and managed by the Primary Clinical Team.

    Treatment with ravulizumab will continue throughout the course of the study unless one of the following events occur: a. An individual loses commercial coverage for ravulizumab; b. Discontinuation of the medication by the clinical team is recommended due to an adverse reaction, intolerability, or inadequate disease control. The decision regarding treatment will be determined by the Primary Clinical Team and the patient; c. The participant prematurely discontinues treatment for personal reasons

    In the event that the medication is discontinued prematurely, participants will continue to be followed throughout the 156 week period with all clinical, radiological, and serological assessments performed.

  3. Clinical surveillance: Clinical safety surveillance will be performed throughout the study and managed by the Primary Clinical Team. In the event of new or concerning clinical symptoms, participants will be evaluated within a 24-hour period via telehealth or in-person visit. Clinical evaluations, serological assessments, and repeat MRI data per protocol will be performed within a 48-hour period. The acute management of subjects will be led by the Primary Clinical Team. All clinical data associated with acute clinical events will be sent to the Core Clinical Committee and relapses adjudicated by consensus. MRI data acquired at the time of the event will be evaluated by the Core Imaging Committee and interval change in conventional imaging outcomes (i.e., new and/or newly enlarging T2-hyperintense lesions, gadolinium enhancement) adjudicated by consensus.
  4. Safety surveillance: Safety assessments in association with treatment with ravulizumab will be managed by the Primary Clinical Team. The use of concomitant medications will be tracked during the entire course of the study. These will include prescribed medications for both NMOSD and non-NMOSD, including the use of glucocorticosteroid treatment administered orally or parenterally, along with over-the-counter agents.
03

Conditions studied

  • Neuromyelitis Optica

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of male and female adult participants recruited from The Multiple Sclerosis and Neuroimmunology Clinic at The University of Texas Southwestern Medical Center in Dallas, Texas.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed available prior to conduct of any study associated activities
  2. Men and women > 18 years of age
  3. Aquaporin-4 IgG positive people with neuromyelitis optica spectrum disorder treated with commercially available ravulizumab in a manner consistent with the approved indication
  4. Expanded Disability Status Scale score of \<7.0

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are intolerant to MRI
  2. Individuals previously exposed to eculizumab with treatment discontinuation due to lack of effective disease control (i.e., clinical relapse or demonstration of MRI advancement after 12 weeks of sustained treatment exposure)
  3. Unresolved meningococcal disease
  4. History of an active infection
  5. Existing participation in neuromyelitis optical spectrum disorder interventional clinical studies
  6. Pregnant or lactating women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • NMOSD

    35 people with aquaporin-4 IgG antibody positive neuromyelitis optica spectrum disorder is planned with all individuals treated with commercially supplied ravulizumab at the recommendation of the healthcare provider, with use consistent with the approved indication and labeling. Approximately 50% of the cohort is anticipated to be Black/African American based on existing internal data.

    Drug: Ravulizumab

Interventions

  • All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.

06

What researchers measure

Primary outcomes

  1. Number of participants with clinical relapses before and after treatment with ravulizumab

    Compare the number of participants with adjudicated clinical relapses both pre- and post-ravulizumab treatment

    Time frame: 52 weeks - 78 weeks in primary phase, 78 weeks in extension phase.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Apr 2029, 57 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Apr 2029 and completion Jun 2027 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
May 3, 2024
StartActual
Jul 10, 2024
Primary completionEst.
Apr 30, 2029was Dec 2026
CompletionEst.
Oct 31, 2029was Jun 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Apr 30, 2029
Oct 13, 2026
Study completion
Jun 30, 2027→Oct 31, 2029
Oct 13, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of participants with clinical relapses before and after treatment with ravulizumab52 weeks - 78 weeks → 52 weeks - 78 weeks in primary phase, 78 weeks in extension phase.
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Dec 31, 2026→Apr 30, 2029
    Study completion Jun 30, 2027→Oct 31, 2029
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of participants with clinical relapses before and after treatment with ravulizumab52 weeks - 78 weeks → 52 weeks - 78 weeks in primary phase, 78 weeks in extension phase.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06398158
Responsible party
Darin Okuda (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
May 3, 2024
Start date
Jul 10, 2024
Primary completion
Apr 30, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Diem Tran, PhD
Contact
diemh.tran@utsouthwestern.edu
214-645-9165
Jose Santoyo
Contact
jose.santoyo@utsouthwestern.edu
214-645-1878
Darin T. Okuda, MD
principal investigator · University of Texas Southwestern Medical Center
Peter Sguigna, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion